Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China

NCT07593248

RecruitingN/A

Sponsor: AstraZeneca

Conditions: Lung Cancer

Countries: China

This is a multi-centre, observational study, with retrospective data collection and prospective active follow-up. The aim is to measure the treatment pattern and real-world outcomes of EGFR-TKI as an adjuvant therapy in patients with early-stage EGFR-mutated NSCLC. The study period ranges from July 1st, 2022 to June 30th, 2031. Approximately 2,000 patients will be enrolled from 15 sites in China.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Diagnosed stage IB-III NSCLC on or prior to the index date;
* Initiated adjuvant EGFR-TKI from July 1st, 2023 to June 30th, 2026
Locations (14)
  • Beijing, China
  • Chengdu, China
  • Fuzhou, China
  • Guangzhou, China
  • Guangzhou, China
  • Nanchang, China
  • Shanghai, China
  • Shenyang, China
  • Shijiazhuang, China
  • Tianjin, China
  • Wuhan, China
  • Xi'an, China
  • Xuzhou, China
  • Zhengzhou, China